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Objectives: To review the literature on the cost-effectiveness of vaccine can beused as a prevention strategy to reduce the incidence rate
dengue vaccination in Southeast Asian countries and possibly to
provide recommendations on promoting dengue vaccination in this
region. Methods: A systematic search was conducted to identify
relevant articles in 3 major databases (ProQuest, American Society
of Tropical Medicine and Hygiene, and PubMed). Complete eco-
nomic evaluation studies, including willingness-to-pay (WTP)
studies, that were conducted in any Southeast Asian country were
included in this study. Systematic review, nonefull-text, and non-
English studies were specifically excluded. Results: Nine selected
studies highlighted the economic evaluation of dengue vaccination in
Southeast Asian countries by consideringmany parameters (eg, vaccine
cost, vaccine efficacy, cost-effectiveness threshold, economic assess-
ment, public acceptance, and WTP). All studies confirmed that dengueConflicts of interest: The authors have indicated that they have n
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In addition, communities provided a good assessment, acceptance, and
WTP value for the vaccine. Conclusions: The use of dengue vaccine
could reduce the burden of disease and economic burden due to
dengue infection in Southeast Asian countries. The efficacy of
dengue vaccine was estimated to be 50-95% for those <9 years, 9
years, and >9 years. In particular, several studies reported that
dengue vaccine could be categorized as a cost-effective intervention
in Southeast Asian countries within certain conditions.
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Over the last decade, dengue fever has been reported to be the
most prevalent arboviral fever worldwide, with up to 40% of the
world's population living in endemic regions and at risk for
dengue infection.1 The dengue virus, which is transmitted
through mosquitoes, has been causing serious problems in
several tropical countries.2 It has been reported that during the
period 2001 to 2010, the number of dengue cases in Southeast
Asian countries was 2.9 million, with 5906 deaths.3 Dengue in-
fections were also related to 1.8 billion cases in Southeast Asian
and Western Pacific countries.4,5
Southeast Asia is one of the regions in the world with a
relatively high incidence rate of dengue infection and a short
epidemic cycle of 3 to 5 years. Several studies reported that
dengue fever in Southeast Asian countries was responsible for
75% of the total disease and economic burden due to denguefever in the world.4,6,7 In particular, an annual economic burden
due to dengue infection in Southeast Asian countries was esti-
mated to be $950 million ($1.65 per capita).3 Several prevention
strategies (eg, surveillance, vector control, and community-based
disease prevention) that have been implemented in these
countries could not be categorized as cost-effective in-
terventions.8 A national surveillance system, which was con-
ducted to determine the incidence rates in the context of
prevention efforts, could not significantly reduce the number
of dengue infections.9 Nevertheless, controlling the vector of
mosquitoes or larvae remains ineffective,10 which might be
caused by the lack of support from the community in compre-
hensive prevention strategies.11
Even though several prevention strategies have been
implemented in Southeast Asian countries, most countries in
this region are still facing a continuous rise in the number of
dengue cases.12,13 Till now, governments are seeking the mosto conflicts of interest with regard to the content of this article.
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ciety for health economics and outcomes research. Published by
Table 1 – Criteria for assessing quality of economic
evaluations.
Design study Setting and location
Type of study
Study perspective
Time horizon
Discount rate
Choice of model
Information about vaccine Vaccine efficacy
Vaccination strategy
Vaccination coverage
Duration of vaccine protection
Cost component Direct and indirect cost
Cost estimation
Vaccination cost
Source of cost
Outcome measurement Cost-effectiveness criteria
Result Incremental cost-effectiveness ratio
Sensitivity analysis
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In the context of giving examples on the situation of dengue
prevention strategies in other regions, dengue vaccination has
been confirmed to be the most cost-effective strategy in
reducing the number of dengue cases, specifically in countries
with a high number of cases and extensive vaccination
coverage.15 Many studies on dengue vaccine, including the
specific vaccine type, mode of action, immune response, and
vaccine effectiveness, confirmed promising results in reducing
the number of dengue infection cases.16e18 A preliminary
clinical trial study, which took into account the correlation
between the vaccine use with its impact on reducing the dis-
ease severity and viral transmission, confirmed a significant
number of prevented infection cases.17 A phase III clinical trial
study in a group of 9- to 16-year-old volunteers to be analyzed
over a period of 25 months indicated that vaccination could
reduce dengue fever (all serotypes) in most (2 out of 3) of the
volunteers and reduce the length of stay.18 In particular, a
previous study confirmed that dengue vaccination in South-
east Asian countries could save medical expenses of up to $17
and highlighted that vaccination was more cost-effective than
vector control strategy.19 Another study also reported that a
vaccination program could reduce 24% of dengue hemorrhagic
fever cases.20 In particular, a previous study in 10 endemic
countries confirmed that dengue vaccination could be highly
cost-effective and a cost-effective intervention in 3 and 7
countries, respectively, according to their gross domestic
product (GDP) per-capita values.21 Despite the fact that dengue
vaccine has been licensed in several Asian countries and has
proven its cost-effectiveness, a postlicensing monitoring and
evaluation (eg, monitoring and registration systems for im-
munization, reporting, and long-term safety assessments) is
still required to be implemented.22
Considering the results from previous studies, it can be sum-
marized that dengue vaccine in many cases has an ability to
reduce the transmission of dengue infection in the community.23
Furthermore, the World Health Organization has confirmed the
potential benefits of dengue vaccine to be implemented into the
national routine immunization program in countries with high
endemicity level as an effort to control dengue infection.24e26
Nevertheless, before the introduction of dengue vaccine, eco-
nomic evaluation studies should be conducted to analyze the
cost-effectiveness of the vaccination program in a specific country
or region, such as in Southeast Asia, which has been highlighted
as one of the regions with the highest prevalence of dengue
infection in the world.27e29 The objective of this study was to
systematically review all published studies on economic evalua-
tions of dengue vaccination in Southeast Asian countries and to
conduct a comprehensive policy recommendation on introducing
dengue vaccine in this region.Methods
Search Strategy
Two of the investigators (W.S. and A.A.S.) searched 3 databases
(ProQuest, American Society of Tropical Medicine and Hygiene
[ASTMH], and PubMed) for all published studies on economic
evaluations of dengue vaccination, including willingness-to-pay
(WTP) studies, in Southeast Asian countries. The search used
the following keywords: “economic evaluation” OR “cost mini-
mization” OR” “cost-effectiveness” OR “cost utility” OR “cost
benefit” OR “willingness-to-pay” AND “dengue” OR “dengue fever”
OR “dengue hemorrhagic fever” AND “vaccine” OR “vaccination”
OR “immunization.”Inclusion and Exclusion Criteria
All complete economic evaluation studies in English that were
conducted in any Southeast Asian country according to the As-
sociation of Southeast Asian Nations and published in the period
2000 to 2017 were included in this study. Nevertheless, system-
atic review studies and studies available in abstracts only were
excluded. From the selected studies, we extracted both qualita-
tive and quantitative data on design study, information about
vaccine, cost component, outcome measurement, and results.
The required criteria of each included article are presented in
Table 1.
In particular, economic results from the analyses were con-
verted into 2016 international dollars by using purchasing power
parities and deflators as measured by the annual growth rate in
the country-specific GDP implicit deflator.30 In case a study did not
specify the year of cost, we assumed the year of cost to be the
same as the year of publication.Results
Literature Search
The literature search identified 162, 60, and 33 original articles in
PubMed, ProQuest, and ASTMH, respectively. We selected 9, 2, and
2 articles after excluding 153, 58, and 31 articles in PubMed, Pro-
Quest, and ASTMH, respectively, because these were pharmaco-
logical and epidemiological studies. From these 13 articles, we
further excluded 4 duplicate articles. In total, there were 9 studies
for final review, as presented in Figure 1.
Our 9 selected studies were from 7 different countries:
Indonesia (n ¼ 3), Singapore (n ¼ 1), Thailand (n ¼ 1),
Philippines (n ¼ 1), Vietnam-Thailand (n ¼ 1), Malaysia (n ¼ 1),
and Southeast Asia (Brunei, Cambodia, Indonesia, Laos,
Malaysia, Myanmar, Philippines, Singapore, Thailand and
Vietnam; n ¼ 1).19,31e38 The oldest article that appeared from
our search was from 2004, focusing on the cost-effectiveness of
a pediatric dengue vaccine in 10 countries in Southeast Asia (ie,
Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar,
Philippines, Singapore, Thailand, and Vietnam),30 and the most
recent one was an article from 2017 addressing the cost-
effectiveness of dengue vaccine in Malaysia.38 The most rele-
vant aspects of these studies are presented in Table 2.
Idenﬁed search through 
PubMed = 161 arcles
Idenﬁed search through 
ASTMH = 33 arcles
Idenﬁed search through 
ProQuest = 60 arcles
Excluded arcles because of 
pharmacology and 
epidemiology studies =
153 arcles
Excluded arcles because of 
pharmacology and 
epidemiology studies =
31 arcles
Excluded arcles because of 
pharmacology and 
epidemiology studies =
58 arcles
9 retrieved studies =
Southeast Asia (1), 
Singapore (1), Thailand (1), 
Malaysia (1), Philippines 
(1), Vietnam Thailand (1) 
and Indonesia (3) 
2 retrieved studies = 
Thailand (1) and 
Philippines (1)
2 retrieved studies = 
Southeast Asia (1) and 
Indonesia (1)
4 arcles were idenﬁed as duplicated arcles
9 included studies to be reviewed in this study
Figure 1 – Literature search from 3 databases. ASTMH indicates American Society of Tropical Medicine and Hygiene.
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Study design and data collection
All selected studies, which have been conducted in specific tar-
geted populations (eg, household, society, and public and private
hospitals), provided information on the economic analysis, the
acceptance, and the WTP value of the society related to the
implementation of dengue vaccination in Southeast Asian coun-
tries. In particular, 4 studies applied cost-effectiveness analysis
(CEA)19,31,33,38 and other studies specifically estimated the public
acceptance and the WTP value of vaccine.34e37 The CEA studies
provided the incremental cost-effectiveness ratio (ICER) by
comparing a scenario of vaccination with that of no vaccination,
so that the difference amount of the cost and outcome for vacci-
nation to be implemented could be estimated.39 Other studies
considered the public acceptance and theWTP value of vaccine as
the outcome parameters by taking the monetary unit into
account.39
A study on cost-effectiveness of a pediatric dengue vaccine in
10 countries, which was conducted by Shepard et al,19 applied a
standard approach to estimating cost-effectiveness values by
comparing 2 scenarios (with vaccination and without vaccina-
tion), evaluating costs and benefits in each scenario, considering
cost per disability-adjusted life-year (DALY) saved, and taking
vector control programs into account. A study by Carrasco et al31
specifically calculated direct and indirect costs of hospitalized and
ambulatory cases due to dengue in Singapore. Data related to in-
direct cost on both cases were collected by using the human-capital and friction cost methods. Two studies in Thailand and
the Philippines calculated ICERs in the context of cost per DALY
averted, compared with no dengue vaccination.32,33 A study by
Shafie et al38 in 2017 evaluated the cost-effectiveness and impact
of dengue vaccination in Malaysia by using a dynamic trans-
mission mathematical model. A multicountry study, which
focused on the householdWTP for dengue vaccination in Vietnam
and Thailand, collected the median value of WTP by assuming
that 50% of the population would purchase vaccine.34 Three pre-
vious studies in Indonesia collected parametric estimates of WTP,
which are sensitive to the choice of distribution and functional
forms of household demand. In particular, demographic infor-
mation of participants was collected to measure the level of
knowledge, attitude, and practice related to dengue vaccine and
other prevention strategies.35e40 More information about study
design and data collection of selected studies is presented in
Table 3.Study perspective, time horizon, discount rate, and use of
mathematical modeling
The choice of perspective in economic evaluation studies is crit-
ical because it determines the cost component that must be
included in the study.39 All the CEA studies applied societal, pro-
vider, and healthcare perspectives.19,31,33,38 Individual perspective
was applied only in those studies that focused on the public
acceptance and the WTP of vaccine.31,34e38
Table 2 – Summary of 9 selected articles on economic evaluations of dengue vaccination in Southeast Asian countries, as published in 2000-2017.
Study Title Setting and location Study objective Type of study Data collection and
analytical methods
Shepard et al19 Cost-effectiveness of a pediatric
dengue vaccine
10 countries in Southeast Asia
(Brunei, Cambodia, Indonesia,
Laos, Malaysia, Myanmar,
Philippines, Singapore, Thailand,
and Vietnam)
To develop a cost-effectiveness
model of dengue vaccination by
focusing on children (aged 15
mo) and using societal
perspective
Cost-effectiveness analysis 1. Cost-effectiveness values were
derived from the cost per DALY
saved
2. Vaccination of the cohort was
compared with the current sit-
uation (no dengue vaccination)
by considering existing vector
control programs
Carrasco et al31 Economic impact of dengue illness
and the cost-effectiveness of
future vaccination programs in
Singapore
Singapore To estimate the cost of illness due
to dengue infection, including
economic burden within DALYs
calculation, and to investigate
the cost-effectiveness of
vaccination program
Cost-effectiveness analysis 1. Indirect costs in hospitalized
and ambulatory cases were
taken into account by using the
human-capital and the friction
cost methods
2. Disease burden was estimated
by considering DALYs
Lee et al32 Economic value of dengue vaccine
in Thailand
Thailand To evaluate the potential health
and economic value of dengue
vaccine administration in 1-y-
old children
Cost-effectiveness analysis 1. ICER was presented in cost per
DALY averted
2. Cost per avoided cases (DHF and
DSS) was calculated by dividing
the incremental cost with the
number of averted cases
Shim33 Dengue dynamics and vaccine
cost-effectiveness analysis in the
Philippines
Philippines To estimate the cost-effectiveness
of dengue vaccination in the
Philippines
Cost-effectiveness analysis 1. Incremental health effects were
estimated from the differences
between the incidence of
dengue infection with and
without the vaccination
program
2. Cost-effectiveness value was
presented in cost per QALY
gained
Lee et al34 A multicountry study of the
household WTP for dengue
vaccination: household survey in
Vietnam and Thailand
Vietnam and Thailand To investigate the economic
benefits of dengue vaccination in
high-risk countries
Cost-benefit analysis 1. Median of WTP was calculated
by estimating 50% of population
would purchase vaccination
2. Parametric estimates of WTP
were considered to be sensitive
on the choice of distribution and
functional form of household
demand
Hadisoemarto
and Castro35
Public acceptance and WTP for a
future dengue vaccine: a
community-based survey in
Bandung, Indonesia
Indonesia To assess parents' WTP for a dose
of dengue vaccine
Cost-benefit analysis 1. Knowledge, attitude, and prac-
tice related to dengue, dengue
prevention, and vaccination, in
general, were measured
2. Public acceptance andWTP for a
dengue vaccine were taken into
account
continued on next page
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Table 2 – continued
Study Title Setting and location Study objective Type of study Data collection and
analytical methods
3. Dengue vaccine acceptance was
correlated with several inde-
pendent variables
Harapan et al36 WTP for a dengue vaccine and its
associated determinants in
Indonesia: a community-based,
cross-sectional survey in Aceh
Indonesia To assess WTP for a dengue
vaccine among community
members and to investigate its
correlation with explanatory
variables
Cost-benefit analysis 1. A cross-sectional survey in
community was applied in this
study
2. A questionnaire was developed
to measure participants' WTP
for a dengue vaccine and to
collect information on their de-
mographic background, eco-
nomic status, history of
episodes of DF, knowledge, atti-
tude, and practice regarding
dengue, and attitude toward
vaccination practice
Harapan et al37 Dengue vaccine acceptance and
associated factors in Indonesia: a
community-based cross-
sectional survey in Aceh
Indonesia To explore the acceptance of
dengue vaccine and its
correlation with explanatory
variables among healthy
inhabitants
Cost-benefit analysis A response variable of dengue
vaccine acceptance and a range
of explanatory variables
(socioeconomic status;
knowledge, attitude, and
practice; attitudes toward
vaccination practice; history of
dengue; and other demographic
data) were covered in the
questionnaires
Shafie et al38 The potential cost-effectiveness of
different dengue vaccination
programs in Malaysia: a value-
based pricing assessment using
dynamic transmission
mathematical modeling
Malaysia To evaluate the cost-effectiveness
and impact of dengue
vaccination in Malaysia from
both provider and societal
perspectives by using a dynamic
transmission mathematical
model
Cost-effectiveness analysis 1. Malaysian-specific data, evi-
dence from the latest phase III
studies, a collection data of
long-term safety, and efficacy
were collected
2. Age-structured deterministic
compartment, vector-host, and
serotype-specific deterministic
compartment models were built
to identify the optimal age of
vaccination and routine
vaccination strategies and/or
mass catch-up vaccination
strategies
3. A value-based pricing was
applied as the cost-effective
threshold price instead of ICER
DALY indicates disability-adjusted life-year; DF, dengue fever; DHF, dengue hemorrhagic fever; DSS, dengue shock syndrome; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted
life-year; WTP, willingness to pay.
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Table 3 –Methodological characteristics of 9 selected articles on economic evaluations of dengue vaccination in Southeast Asian countries, as published in 2001-2017.
Study Study
perspective
Comparison Time horizon Discount rate Choice of model Parameters in the
sensitivity analysis
Shepard et al19 Societal Comparing vaccination with no
vaccination and vector control
program
66 y 15% (commercial
sector) and 6%
(public sector)
NR Costs per dose that was based on
the lowest and highest price of
HBV vaccine in developing
countries; use of other vaccines;
degree of illness, which was
based on alternative value of
Gubler and Meltzer; and value of
DALYs
Carrasco et al31 Individual Comparing vaccination with no
vaccination and vector control
program
75 y 18% NR Symptomatic level in each age
group; duration of symptoms of
DHF; defect weight of DF cases;
proportion of dengue cases; total
estimated cost for hospital cases;
hospitalization cost per day;
length of stay in hospital; and
currency fluctuations
Lee et al32 Societal Comparing vaccination with no
vaccination
1 y 3% Markov simulation model Vaccine costs; vaccine efficacy; risk
of infection; and specific
threshold value for each country
Shim33 Healthcare and
societal
Comparing the use of vaccine
(continuously on 9-y-old and 1-y-
old catch-up with target of
children between 9 and 15 y old)
with no vaccination
20 y 3% Mathematical model of den ue
transmission and vaccina ion
Symptoms; disease stage; type of
treatment; age-dependent
vaccine efficacy; and loss of
immunity
Lee et al34 Individual NR NR NR NR NR
Hadisoemarto
and Castro35
Individual NR NR NR NR NR
Harapan et al36 Individual NR NR NR NR NR
Harapan et al37 Individual NR NR NR NR NR
Shafie et al38 Provider and
societal
perspectives
Comparing vaccination with no
vaccination
5-30 y 0% Dynamic transmission
mathematical modeling
Geographical location; routine
population age group; coverage
rate; vaccine administration
cost; compliance; vaccine
wastage; vaccine efficacy;
vaccine average duration of
protection; underreporting
factors; catch-up cohort
coverage, catch-up cohort
compliance; case-fatality rate;
and treatment cost
DALY indicates disability-adjusted life-year; DHF, dengue hemorrhagic fever; HBV, hepatitis B virus; NR, not reported.
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Table 4 – Vaccine information.
Study Vaccination strategy Duration of vaccine
protection
Vaccination coverage Measurement of
effectiveness
Shepard et al19 2- or 3-dose vaccine at age
of 9, 12, and 18 mo
10 y 70% (lowest coverage level
in SEAR, according to the
coverage of measles
vaccination in several
countries)
Vaccination was estimated
to be 95% efficacious in
providing lifetime
protection against each
dengue virus serotypes
and 0.25% reduction in
recipients' annual risk of
infection
Carrasco et al31 2- and 3-dose vaccine 10 y 75% Vaccine efficacy was
estimated to be 80%,
which was relatively low
(compared with that in
previous studies)
Lee et al32 3-dose vaccine 10-30 y NR Vaccine efficacy varied in a
range of 50%-95%
Shim33 2 strategies: A (given to 9-y-
old children) and B (given
to 9- to 15-y-old children,
and 9-y-old children
through catch-up and
routine program)
NR NR Vaccine efficacy was
estimated to be 61.1%,
79.2%, and 90.9% against
infection among
seronegative group of9 y
old, seropositive group of
9 y old, and against DHF
among seropositive group
of 9 y old, respectively
Lee et al34 3-dose 10-30 y NR Vaccine efficacy 70% and
95%
Hadisoemarto
and Castro35
NR NR NR NR
Harapan et al36 NR NR
Harapan et al37 NR NR NR NR
Shafie et al38 3-dose vaccine at school-
based (9-17 y old) and
community-based age
(18-30 y old); routine and
catch-up strategies were
taken into account
10 y 20%-80% and 90%-100%
(including coverage for
catch-up cohort in several
strategies)
Vaccine efficacy was
estimated to be 55.7%-
64.5% according to pooled
phase III efficacy data;
relative efficacy against
infection was estimated
in a range of 0%-100% for
ambulatory cases
DHF indicates dengue hemorrhagic fever; NR, not reported; SEAR, Southeast Asian Region.
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associated with the application of time horizon. The calculation of
benefit-to-cost ratio in a long-term intervention, such as vacci-
nation, should consider a long time horizon (>1 year). Five
selected CEA studies applied 5 different time horizons: 1 year, 20
years, 65 years, 71 years, and 5 to 30 years,19,31e33,38 whereas other
studies did not take this into account.When a study applies a time
horizon of more than 1 year, the health effect and cost should be
adjusted with a discounting rate. Four selected CEA studies
applied 4 specific discount rates: 3%, 6%, 15%, and 18%.19,31e33,38
Other studies did not apply a discount rate (see Table 3).
From all the selected studies, only 3 studies tookmathematical
modeling into account.32,33,38 A study by Lee et al32 developed a
decision-analytic Markov simulation model to estimate the cost-
effectiveness value of implementing a dengue vaccine to a pop-
ulation of 1-year-olds or younger in Thailand from a societal
perspective.32 In addition, a study in the Philippines by Shim33
developed an age-structured model of dengue transmission and
vaccination by comparing 2 vaccination scenarios entailingroutine vaccination programs both with and without catch-up
vaccination. Shafie et al38 applied a dynamic transmission
mathematical model to evaluate the cost-effectiveness and
impact of dengue vaccination in Malaysia. More detailed infor-
mation is presented in Table 3.Sensitivity analysis
Because economic evaluation studies should consider the uncer-
tainty aspect of various used parameters, it seems critical to
analyze the impact of these uncertain parameters by conducting a
sensitivity analysis. In this study, only 5 selected studies con-
ducted sensitivity analyses by considering various parameters,
such as vaccine price, use of other vaccines, dengue diagnoses and
symptoms, duration of illness, degree of dengue fever, estimated
costs of illness, threshold values, vaccine mechanisms, and im-
pacts on decreased transmission rates or dengue spread.19,31e33
Differing with other studies, Shafie et al38 considered more pa-
rameters in the sensitivity analyses, such as geographical
Table 5 – Cost elements.
Study Cost estimation
Shepard et al19 Secondary data from medical expenses in the
hospital (outpatient and inpatient cases) and
primary data (travel expenses and parents'
time lost)
Carrasco et al31 Direct medical costs (hospitalized and
ambulatory cases), direct nonmedical costs,
and disability weights (DF and DHF cases)
Lee et al32 Costs of vaccination, clinical visit, hospital visit,
vaccine minor side effect, and disability weight
Shim33 Direct medical costs for healthcare perspective
and direct and indirect costs for societal
perspective
Lee et al34 Vaccination cost
Hadisoemarto
and Castro35
Vaccination cost
Harapan et al36 Vaccination cost
Harapan et al37 Vaccination cost
Shafie et al38 Treatment and vaccination costs from provider
and societal perspective
DF indicates dengue fever; DHF, dengue hemorrhagic fever.
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administration cost, compliance, vaccine wastage, vaccine effi-
cacy, vaccine average duration of protection, underreporting fac-
tors, catch-up cohort coverage, catch-up cohort compliance, case-
fatality rate, and treatment cost.
Vaccine information
Most of the studies (n ¼ 5) focused on the use of a 3-dose
vaccine19,31e34 and 2 of them made a further comparison be-
tween the use of 3-dose and 2-dose vaccines.37,39 Targeted age
groups varied from the ages of 6, 12, and 18 months to younger
than 9, 9, and older than 9 years.19,31e34,38 The protective duration
of vaccine was estimated to be 10 years19,31,38 and 10 to 30
years,32,33 whereas the coverage of vaccination was estimated to
be 20% to 80%, 70%, 75%, and 90% to 100%.19,31,38 Regarding vac-
cine efficacy, several studies estimated the values to be 50%, 55.7%
to 64.5%, 70%, 80%, and 95%.19,32,34,38 Only 1 study specifically
estimated the vaccine efficacy on the basis of age: younger than 9
years (61.6%), 9 years (79.2%), and older than 9 years (90.9%).33 All
information about vaccine is presented in Table 4.
Cost estimation
Costs or opportunity costs are defined as the value of lost oppor-
tunities as a result of resource use in an activity.39 In economic
evaluation studies, cost appears to be an important aspect to be
estimated because of its limited resources in many countries,
including Southeast Asian countries. All studies estimated the
vaccination cost.19,31e38 Four studies calculated direct and indirect
costs because they applied a societal perspective.19,31e33,38 In
particular, 2 studies took disability weights into account32,33 and
only 1 study considered the cost of minor side effects due to
vaccination (see Table 5).32
Primary results
All studies considered vaccine price and administration cost to
estimate total vaccination cost. Shepard et al19 applied vaccine
prices of $0.50 and $10.00 for the public and private sectors,
respectively. Carrasco et al31 considered vaccine prices of $58.90 (3doses with 10 years of immunity) and $319.00 (2 long-lived im-
mune doses).31 A range of $0.12 to $65.70 (total for 3 doses) was
applied in Thailand.32 Lee et al34 considered vaccine prices at a
range of $0.0004 to $0.04 and $0.16 to $39.34 in Vietnam and
Thailand, respectively.34 A WTP study in Indonesia applied vac-
cine prices of $0.0002 to $0.004.35,36 Administration cost varied
from $0.50 to $6.00 (see Table 6).19
Shepard et al19 confirmed that the incremental cost of vacci-
nating 1 child against dengue would be $4.85/DALY and $39.10/
DALY in the public and private sectors, respectively.19 In partic-
ular, a study in Singapore mentioned that the thresholds for
vaccination to be cost-effective in Singapore would range from
$105.70 to $546.30 per dose.31 A study in Thailand showed that
vaccination would be a highly cost-effective intervention (ICER
< 4289) for all scenarios under certain conditions, such as a point
of vaccine price at $4.93, a dominated vaccine efficacy of at least
75%, and an administration cost of a 3-dose vaccine at $0.12 or
less.32 A study in the Philippines confirmed that dengue vaccina-
tion would be cost-effective at a WTP value of $0.15 per quality-
adjusted life-year (QALY) in 69% of the model iterations. This
likelihood of cost-effectiveness would increase up to 74% within
an acceptability threshold of $0.46/QALY.33 Lee et al34 highlighted
that the WTP values of vaccine were $0.004 ($0.002 per dose) and
$5.56 ($1.85 per dose) in Vietnam and Thailand, respectively.34
Hadisoemarto and Castro35 observed that distribution of
maximum WTP in Indonesia was achieved when 37.2% of par-
ticipants expressed their WTP to be below $0.0003. Another study
by Harapan et al36 reported that the mean and median values of
WTP on dengue vaccine were $0.001 (95% confidence interval [CI]
3.86-4.23) and $0.001 (95% CI 3.74-4.23), respectively.36 In addition,
Shafie et al38 confirmed that the best vaccination strategy to be
implemented in Malaysia was a routine vaccination program for
the age of 13 years, coupled with a catch-up program for the age of
14 to 30 years. The total price per dose values of $50 491 to $95 372
and $23 843 to $44180 were likely to be cost-effective and highly
cost-effective thresholds, respectively, from the provider
perspective. The highly cost-effective threshold could even be
$21038 to $24 544 by assuming no underreporting cases in
Malaysia (see Table 6).38Discussion
Dengue vaccination is considered to be one of the most cost-
effective interventions to prevent the spread of dengue fever in
many countries within certain conditions. Nevertheless, more
scientific evidences regarding its potential benefits are still
required because the number of its economic evaluation studies
and the use of vaccine itself are still very limited. Economic
evaluation studies that have been conducted in several countries
applied a modeling approach to predict the economic impact of
vaccination by considering several alternative scenarios.40,41
Nevertheless, the implementation of modeling studies on the
cost-effectiveness of dengue vaccine appears to be crucial before
the introduction of dengue vaccine itself in each specific country.
Most of the studies in this area applied aMarkov simulationmodel
and dynamic transmissionmodel, which took herd immunity into
account.32,38,42 The models differed in assumptions and parame-
ters related to the natural history and ecology of dengue in both
humans and mosquitoes.24
All included studies targeted a population group that had a
relatively high risk of dengue infection in all settings (hospitals,
communities, or households), which can be extrapolated into the
general population. Several perspectives (eg, societal, individual,
provider, payer, and healthcare perspectives) were applied to es-
timate the cost of illness due to dengue infection. Nevertheless,
the determination of perspective was based on the research
Table 6 – Primary result (in 2016 international dollars).
Study Vaccination cost Primary result
Vaccine price Administration cost
Shepard et al19
(in Southeast Asia 2001)
$0.50 and $10 per dose in the
public and private sectors,
respectively
$4.14 1. Vaccination could reduce 82%
of mortality and morbidity
burdens of disease by saving
0.34 DALYs/1000 population/y.
2. Incremental cost of vaccina-
tion would be 4.85/DALY and
8.28/DALY in the public and
private sectors, respectively.
3. Cost-effectiveness ratio for an
environmental management
approach to dengue preven-
tion and control was esti-
mated to be 3 139/DALY.
Carrasco et al31
(in Singapore 2010)
$58 for a 3-dose vaccine with a
10-y duration of immunity and
$319 for a 2-dose vaccine with a
lifetime duration of immunity
NR 1. Total economic costs in 2000-
2009 were $1.01 billion and
$0.95 billion from the human-
capital and friction cost
method, respectively.
2. Average DALYs per 100 000
population were estimated to
be 8.7 (5th and 95th percentiles
of 8 and 10) and 14 (5th and
95th percentiles of 13 and 16)
when using constant symp-
tomatic rates and age-depen-
dent symptomatic rates,
respectively.
3. Cost-effectiveness values
ranged from $77.90 per dose (a
3-dose vaccine within a 10-y
immunity) to $235.86 per dose
(a 2-dose vaccine within a
lifetime immunity), which
were lower than the threshold
for vaccination program to be
cost-effective in Singapore.
Lee et al32 (in Thailand 2010) $0.12-$65.7 for total doses in a
3-dose vaccine
NR 1. Vaccination was estimated to
be highly cost-effective (ICER
< 4289) for all scenarios at a
vaccine price of up to $4.93
and would dominate (less
costly and more effective) in
most scenarios at a vaccine
efficacy of at least 75% when
the total cost of a 3-dose vac-
cine was $0.12 or less.
2. Vaccination remained to be
cost-effective (4289 > ICER
< 12868) at vaccine prices of
$16.40 and $32.87 when the
vaccine efficacy and infection
incidence were applied to be at
least 75% and 9%,
respectively.
3. Vaccinationwould not be cost-
effective when the incidence
rate of infection was <9%,
vaccination cost was >$24.65,
and vaccine efficacy was
<50%.
continued on next page
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Table 6 – continued
Study Vaccination cost Primary result
Vaccine price Administration cost
4. Vaccination was even proved
to be cost-effective at a vac-
cine price of $65.73, vaccine
efficacy of 95%, and infection
risk of 15%.
Shim33
(in Philippines 2016)
From the healthcare perspective, the threshold for vaccination to be
cost-effective was estimated to be $3.90 and $4.00 for strategy A and B,
respectively
From the societal perspective, the threshold was estimated to be $4.00
and $4.12 for strategy A and B, respectively
From the health and societal
perspectives, at WTP values of
$153.97 (1 GDP per capita)
and $461.9 (3 GDP per capita),
the likelihood of vaccination to
be cost-effective would be 68%-
69% and 74%, respectively.
Lee et al34
(in Vietnam and Thailand 2012)
Vietnam: $0.0004, $0.002, $0.003,
$0.006, and $0.04
Thailand: $0.16, $0.79, $2.38,
$4.80, and $39.34
NR The conservative Turnbull lower
bound mean of WTP was
calculated to be $1.14 and $1.85
per dose in Vietnam and
Thailand, respectively. The
parametric median ofWTP was
calculated to be $0.71 and $1.89
per dose in Vietnam and
Thailand, respectively.
Hadisoemarto and Castro35
(in Indonesia 2010)
$0.0003-$0.003 NR A total of 94.2% of the
participants expressed that
theywere likely or very likely to
vaccinate their children.
Distribution of maximum WTP
was observed to be 1.8%-37.2%.
Harapan et al36
(in Indonesia 2015)
$0.70-$14.70 NR Most participants (87.5%)
confirmed that they were
willing to pay for a dengue
vaccine. The mean and median
values of participants' WTP
were estimated to be 4.04 (95%
CI 3.86-4.23) and 3.97 (95% CI
3.74-4.23), respectively. In
particular, approximately 6.4%
of participants were unwilling
to accept a dengue vaccine
even if the vaccine was
provided for free, and 6.1% of
participants stated that they
would accept the vaccine only
if it was provided for free.
Harapan et al37
(in Indonesia 2015)
NR NR Approximately 37.6% and 39.7%
of participants expressed that
they were likely and very likely
to vaccinate their children (if
they had children),
respectively. About 5% of
participants were unable to
decide. When dichotomizing
vaccine acceptance into willing
and nonwilling, the acceptance
rate would be 77.3%.
Shafie et al38
(in Malaysia 2013)
Direct vaccination program cost
per dose from the societal
perspective would be the same
as that from the provider
perspective ($2510)
Vaccine administration cost per
dose would be $2510 and $4179
from provider and societal
perspectives
The best vaccination strategy to
be implemented in Malaysia
was program 1, which
considered a routine
vaccination program for the
age group of 13 y, coupled with
continued on next page
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Table 6 – continued
Study Vaccination cost Primary result
Vaccine price Administration cost
a catch-up program for the age
group of 14-30 y. The total price
per dose values of $50 491-
$95 372 and $23843-$44 180
were likely to be cost-effective
and highly cost-effective
thresholds, respectively, from
the provider perspective. Even,
the highly cost-effective
threshold could be $21 038-
$24 544 by assuming no
underreporting cases.
CI indicates confidence interval; DALY, disability-adjusted life-year; GDP, gross domestic product; ICER, incremental cost-effectiveness ratio;
NR, not reported; WTP, willingness to pay.
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by comparing the use of vaccine with a situation of no vaccine and
other scenarios (eg, vector control) to determine the best scenario
or strategy in terms of cost-effectiveness values (cost/DALY or
cost/QALY). Regarding the sensitivity analysis, several studies
considered the mean burden of disease, total cost, and benefit-
cost ratio of the vaccination program, parameters related to the
lifetime immune system and duration of dengue symptoms, and
discount rate.
Several studies reported the values of vaccine efficacy to be
50%, 70%, 80%, and 95%.19,31,32,34 A study by Shim33 specifically
mentioned values of vaccine efficacy in different age groups (<9
years: 61.6%; 9 years: 79.2%; and >9 years: 90.9%). These findings,
however, are correlated with the fact that vaccination could
reduce the mortality, morbidity, and disease burden by 82%.19 A
previous study also reported that a potential dengue vaccine has
an ability to reduce the burden of dengue disease in moderate
and high endemicity areas,24 with a rate of efficacy for symp-
tomatic dengue during the first 25 months being 60.3% (95% CI
55.7-64.5).43 It has also proven to be able to reduce dengue fever in
4 serotypes (by 2/3 of the total volunteers), to prevent dengue
cases (from 9 dengue cases), and to reduce the length of stay (8 out
of 10 cases of dengue).18 The efficacy of the vaccine on the specific
serotype was reported to be 50.3%, 42.3%, 74.0%, and 77.7% for
serotypes 1, 2, 3, and 4, respectively. Furthermore, a 3-dose
regimen of CYD-TDV has been confirmed to have a good safety
profile in a group of 2- to 11-year-olds with a history of yellow
fever vaccination and elicited robust antibody responses that
were balanced against the 4 serotypes.44 The safety and immu-
nogenicity of CYD-TDV have also been demonstrated through
independent phase I trials in the United States and Colombia,45
which confirmed that the safety profile of the CYD-TDV vaccine
was similar to that of the placebo, with no marked difference in
rates of adverse events.46 The risk in seronegative vaccine re-
cipients was higher than in seronegative controls, and the risk of
severe virologically confirmed dengue in seropositive vaccine re-
cipients was also lower than in seropositive controls.47 In partic-
ular, pain at the injection site, itching, and mild erythema were
the most common side effects that could be found in all age
groups.48
Even though dengue vaccine has the potential to reduce the
burden of dengue disease, specifically in moderate and high
endemicity areas, it has not yet been included in existing im-
munization programs in many countries.24 Because aneconomic evaluation study is required by the government or
insurance companies as a consideration on decision-making
process, it should be comprehensively conducted to enable
policy makers to make decisions more precisely while allo-
cating resource and budget because in some countries, such as
in Southeast Asian countries, dengue vaccination might be
heavily subsidized by the government and would have an
impact on healthcare policies.49 The results on CEA of dengue
vaccine in this study demonstrated that dengue vaccine can be
considered as a cost-effective intervention, which might be
developed and implemented in all regions.50 It has been high-
lighted that the total cost of using dengue vaccine in Southeast
Asia would be approximately $81.7 million annually, which
could save $72.7 million compared with conventional treat-
ment. Furthermore, about 1 million cost-effectiveness ratio of
dengue vaccination would save 20 000 DALYs. The least costly
or unfavorable cost-effectiveness ratio would be $683/DALY and
the cost-effectiveness ratio with low vaccine efficacy would be
$788 to $960/DALY, which were still lower than GDP per capita
in Southeast Asian countries ($1083).19 In particular, because
vaccination is considered to be a long-term investment with
high initial costs, the best vaccination strategy should be
considered by the stakeholder. A study in Malaysia highlighted
the potential of a routine vaccination program for the age of 13
years that was coupled with a catch-up program for the age of
14 to 30 years, which could be considered as the best vaccina-
tion strategy in the context of morbidity and mortality
averted.38
Despite the fact that this study has several limitations, such
as the high heterogeneity among the included studies, and its
inability to take into account the prevalence rate in the search
strategy and the cost of overcoming side effects because of its
relatively low cost, policy makers in Southeast Asian countries
can consider this study to review evidence from all published
studies on economic evaluations of dengue vaccination in
Southeast Asian countries so as to conduct a comprehensive
policy recommendation on introducing dengue vaccine in this
region. Nevertheless, dengue vaccination has been proven to be
a cost-effective intervention in several prioritized countries
within certain age groups.26 In a country with a relatively high
burden of dengue infection, vaccination appears to be a very
promising intervention. Yet, vaccine price is considered to be
the most influential parameter in the cost-effectiveness val-
ue.51e53 This situation should be highlighted by policy makers
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sustainably implemented in this region.Conclusions
The implementation of dengue vaccination could reduce the
burden of disease and economic burden due to dengue infection
in Southeast Asian countries. The efficacy of dengue vaccine was
estimated to be 50% to 95% for those younger than 9 years, 9 years,
and older than 9 years. In particular, several studies reported that
dengue vaccination could be categorized as a cost-effective
intervention in Southeast Asian countries within certain
conditions.Source of Financial Support
This study was funded by the Ministry of Research, Technology
and Higher Education, Republic of Indonesia (Grant number: 391/
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